



PHA 4142.2 (2891/3)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Peter C. Isakson et al.

Art Unit 1639

Serial No. 10/038,080

Filed January 3, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED  
DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR  
AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST

Examiner Jon D. Epperson Ph.D.

January 27, 2005

**TERMINAL DISCLAIMER TO OBLIGATE A PROVISIONAL DOUBLE  
PATENTING REJECTION OVER A PENDING SECOND APPLICATION**

TO THE COMMISSIONER FOR PATENTS,

SIR:

The owner, Pharmacia Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number US 2004/0106668, filed on July 10, 2003, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second

application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. [ ] For submission on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of organization  
I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

2. [X] The undersigned is an attorney of record.

January 27, 2005  
Date

  
Signature

Kathleen M. Petrillo  
Typed or Printed Name

- [X] Terminal disclaimer fee under 37 CFR 1.20(d) is included
- [X] PTO suggested wording for terminal disclaimer was
  - [X] unchanged
  - [ ] changed (if changed, an explanation should be supplied)

Express Mail Label No. EV 453250791 US